What is the price target for EHC stock?
16 analysts have analysed EHC and the average price target is 144.07 USD. This implies a price increase of 47.78% is expected in the next year compared to the current price of 97.49.
NYSE:EHC • US29261A1007
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ENCOMPASS HEALTH CORP (EHC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-06 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-30 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-02 | UBS | Maintains | Buy -> Buy |
| 2025-09-16 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-09-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-06 | UBS | Maintains | Buy -> Buy |
| 2025-06-05 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-27 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-28 | UBS | Maintains | Buy -> Buy |
| 2025-04-28 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-28 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-04-25 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-25 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-10 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-02-07 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-10-29 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-10-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-14 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-11 | Keybanc | Initiate | Overweight |
| 2024-09-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-25 | UBS | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.801B 10.41% | 5.373B 11.91% | 5.935B 10.46% | 6.492B 9.38% | 7.02B 8.13% | 7.565B 7.76% | 8.019B 6.00% | |
| EBITDA YoY % growth | 1.006B 15.09% | 1.164B 15.75% | 1.381B 18.63% | 1.389B 0.58% | 1.503B 8.21% | 1.656B 10.18% | N/A | |
| EBIT YoY % growth | 731.8M 16.12% | 864.5M 18.13% | 1.053B 21.82% | 1.069B 1.51% | 1.163B 8.79% | 1.259B 8.25% | N/A | |
| Operating Margin | 15.24% | 16.09% | 17.74% | 16.47% | 16.57% | 16.64% | N/A | |
| EPS YoY % growth | 3.64 6.74% | 4.43 21.70% | 5.46 23.25% | 6.02 10.23% | 6.54 8.66% | 7.24 10.75% | 7.77 7.24% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.52 10.84% | 1.50 7.22% | 1.38 12.36% | 1.45 -0.68% | 1.60 5.34% | 1.58 5.08% | 1.46 5.51% | 1.49 2.82% |
| Revenue Q2Q % growth | 1.592B 9.39% | 1.594B 9.35% | 1.619B 9.58% | 1.688B 9.28% | 1.737B 9.11% | 1.738B 9.03% | 1.757B 8.52% | 1.823B 8.00% |
| EBITDA Q2Q % growth | 346.48M 0.08% | 345.46M -17.39% | 332.13M -31.53% | 342.71M -43.94% | 369.58M 6.67% | 369.04M 6.83% | 360.17M 8.44% | 365.7M 6.71% |
| EBIT Q2Q % growth | 269.38M 0.89% | 267.14M 3.10% | 251.64M 3.30% | 256.1M -9.63% | N/A | N/A | N/A | N/A |
All data in USD
16 analysts have analysed EHC and the average price target is 144.07 USD. This implies a price increase of 47.78% is expected in the next year compared to the current price of 97.49.
ENCOMPASS HEALTH CORP (EHC) will report earnings on 2026-04-22, after the market close.
The consensus EPS estimate for the next earnings of ENCOMPASS HEALTH CORP (EHC) is 1.52 USD and the consensus revenue estimate is 1.59B USD.
The consensus rating for ENCOMPASS HEALTH CORP (EHC) is 87.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.